Preparation and application of an organotin complex with mitochondrial targeting function

By synthesizing organotin complexes of triphenylamine carboxylic acid with mitochondrial-targeting fluorescent properties, the problems of high toxicity and poor selectivity of existing organotin complexes in the field of antitumor treatment have been solved. This has achieved highly efficient in vitro antitumor activity and mitochondrial-targeting localization, making it suitable for the development of XDC drugs.

CN123106746APending Publication Date: 2026-11-17LIAOCHENG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611487283.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-23
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing organotin complexes have problems such as high toxicity and poor selectivity in the field of anti-tumor treatment, and no complexes that combine mitochondrial targeting, fluorescence imaging and anti-tumor activity have been reported.

Method used

A 4',4''',4''''-aminotris[3-fluoro-(1,1'-biphenyl)-4-carboxylic acid] organotin complex was designed and synthesized. A triphenylamine carboxylic acid compound with mitochondrial-targeting fluorescence was prepared by coordination reaction for targeting mitochondria to induce cancer cell death.

Benefits of technology

It achieved excellent in vitro antitumor activity and clear mitochondrial targeting ability, which is significantly better than traditional cisplatin drugs. It has potential pharmaceutical value and can be used as an effective payload or targeting ligand for XDC drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106746A_ABST
    Figure CN123106746A_ABST
Patent Text Reader

Abstract

This invention discloses the preparation and application of an organotin complex with mitochondrial targeting function, belonging to the fields of medicinal chemistry and antitumor drug technology. The organotin complex is a 4',4''',4''''-aminotris[3-fluoro-(1,1'-biphenyl)-4-carboxylic acid] organotin complex, with a triclinic crystal system and space group P-1. This complex exhibits excellent in vitro proliferation inhibitory activity against human lung cancer cells A549, human liver cancer cells HepG2, human breast cancer cells MCF-7, and human cervical cancer cells HeLa, with an IC500%. 50 The concentration ranges from 0.19 to 0.65 μM, significantly superior to cisplatin, a first-line clinical drug, and exhibits clear mitochondrial targeting ability. The organotin complex provided by this invention can effectively trigger tumor cell apoptosis pathways through a mitochondrial targeting strategy, alleviating drug resistance issues caused by DNA repair mechanisms in traditional platinum-based drugs. This invention also discloses the preparation method of this complex and its application as an antitumor drug.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedical technology, specifically to the preparation and application of an organotin complex with mitochondrial targeting function. Background Technology

[0002] Mitochondria, as vital organelles for energy production in cells, participate in biological processes such as the electron transport chain and the tricarboxylic acid cycle, playing a central role in the regulation of cellular function, metabolism, and cell death. Altered mitochondrial metabolism can increase the production of reactive oxygen species (ROS), alter cellular redox states, and regulate the appropriate balance between pro-apoptotic and anti-apoptotic molecules. Therefore, given mitochondria's key role in cell death pathways and its unique position in cancer cell energy metabolism, mitochondria have become a potential target in cancer treatment strategies. Recent studies have reported on triphenylamine carboxylic acid and its derivatives, finding that they not only possess excellent fluorescence properties for cell imaging and tracking, but the triphenylamine backbone, acting as an excellent electron donor and fluorophore, is crucial for these functions. Furthermore, organotin carboxylic acid esters have attracted widespread attention in the anti-tumor field due to their unique biological activities; however, traditional organotin complexes generally suffer from high toxicity and poor selectivity, limiting their clinical application. Currently, however, there are no reports of complexes using triphenylamine carboxylic acid as the active ligand that simultaneously integrate mitochondrial targeting, fluorescence imaging, and organotin anti-tumor activity. Therefore, this invention uses triphenylamine carboxylic acid as a mitochondrial-targeting fluorescent ligand and organotin as a metal active center to synthesize a mitochondrial-targeting fluorescent triphenylamine carboxylic acid organotin compound through coordination reaction, and studies its effect of targeting mitochondria to induce cancer cell death and its application in anticancer drugs. Summary of the Invention

[0003] This invention provides an organotin complex with mitochondrial targeting function, along with its preparation method and its application in anticancer drugs. The complex exhibits excellent in vitro antitumor activity and a clear mitochondrial targeting ability, and can serve as an effective component of anticancer drugs, as well as a payload or targeting ligand for XDC drugs. The specific technical solution is as follows: A triphenyltin complex, a 4',4''',4''''-aminotris[3-fluoro-(1,1'-biphenyl)-4-carboxylic acid]organotin complex, has the structural formula shown in Formula I:

[0004] Formula I Preferably, the 4',4''',4''''-aminotris[3-fluoro-(1,1'-biphenyl)-4-carboxylic acid]organotin complex is triclinic, space group P-1, a = 12.9229(12) Å, b = 14.2199(13) Å, c = 27.022(3) Å, α = 76.774(2). o , β = 82.241(3) o , γ = 73.8650(10), Z = 2, V = 4630.0(7) Å, Dc = 1.224Mg / m 3 , μ = 0.856 Å, F(000)=1712.

[0005] Preferably, the triphenyltin complex is a pale yellow transparent crystal with a melting point of 240-242 °C.

[0006] Application of the 4',4''',4''''-aminotris[3-fluoro-(1,1'-biphenyl)-4-carboxylic acid] organotin complex in the preparation of anticancer drugs.

[0007] Preferably, the cancer is lung cancer, liver cancer, breast cancer, or cervical cancer.

[0008] Preferably, the lung cancer, liver cancer, breast cancer, and cervical cancer are derived from human lung cancer cells A549, human liver cancer cells HepG2, human breast cancer cells MCF-7, and human cervical cancer cells HeLa, respectively.

[0009] The above-mentioned triphenyltin complex is prepared by reacting 4',4''',4'''''-aminotris[3-fluoro-(1,1'-biphenyl)-4-carboxylic acid] with bis(triphenyltin) oxide as raw material.

[0010] Preferably, in the above preparation method, 4',4''',4''''-aminotris[3-fluoro-(1,1'-biphenyl)-4-carboxylic acid] and bis(triphenyltin) oxide are added to anhydrous ethanol and reacted until complete, then cooled and rotary evaporated to obtain a pale yellow powder.

[0011] Preferably, the above preparation method involves dissolving the pale yellow powder in a solvent, evaporating it, and then crystallizing it to obtain the final product.

[0012] Preferably, the molar ratio of 4',4''',4''''-aminotris[3-fluoro-(1,1'-biphenyl)-4-carboxylic acid] to bis(triphenyltin) oxide is 2:3.

[0013] Preferably, the reaction is carried out at 70 °C for 12 h, and the crystallization is carried out at 15~30 °C.

[0014] To address the problems associated with 4',4''',4''''-aminotris[3-fluoro-(1,1'-biphenyl)-4-carboxylic acid] and its derivatives, the inventors designed and prepared an organotin complex of 4',4''',4''''-aminotris[3-fluoro-(1,1'-biphenyl)-4-carboxylic acid]. The structure of this complex, determined by infrared spectroscopy, nuclear magnetic resonance, and X-ray single-crystal diffraction, is Formula I.

[0015] The structural feature of the 4',4''',4''''-aminotris[3-fluoro-(1,1'-biphenyl)-4-carboxylic acid] organotin complex of the present invention is that the tin atoms in the molecule are tetrahedral with four coordination positions, which gives it a certain degree of thermal stability.

[0016] Accordingly, the inventors also established a corresponding preparation method, which involves adding 4',4''',4''''-aminotris[3-fluoro-(1,1'-biphenyl)-4-carboxylic acid] and bis(triphenyltin) oxide to anhydrous ethanol and reacting until complete. Then, the mixture is cooled and concentrated under reduced pressure to obtain a yellow-green solid. The solid is then recrystallized from dichloromethane and diethyl ether (2:8) to obtain a yellow-green crystalline compound.

[0017] The advantages and effects of this application are as follows: This invention provides a method for synthesizing triphenyltin complexes targeting mitochondria and their applications; and investigates their effects on A549, HepG-2, and MCF. 7. Inhibitory activity against the proliferation of HeLa cells. MTT assay results showed that the target complexes, A549, HepG-2, and MCF, inhibited the proliferation of HeLa cells. 7 and HeLa exhibited good in vitro inhibitory activity, significantly superior to classic cisplatin-based anticancer drugs. Further studies demonstrated that the target complex could localize to the mitochondrial region, exhibiting green fluorescence. More importantly, based on its extremely high in vitro antitumor activity (IC50... 50 Values ​​ranged from 0.19 to 0.65 μM (see Table 1) and demonstrated clear mitochondrial targeting ability (see Example 3 and...). Figure 4 The complexes of this invention can serve as core functional modules (payloads or targeting ligands) for XDC drug development. They can be coupled to targeting carriers such as antibodies via linkers, providing key compounds for constructing novel targeted anti-tumor XDC drugs.

[0018] In summary, the 4',4''',4''''-aminotris[3-fluoro-(1,1'-biphenyl)-4-carboxylic acid] organotin metal complex of the present invention exhibits high anticancer activity, low cost, and a simple preparation method, demonstrating significant potential pharmaceutical value. Furthermore, the complex of the present invention shows broad application prospects as an effective payload or targeting ligand for XDC drugs, providing an important material basis for the innovative development of XDC drugs and holding promise for the preparation of various antitumor XDC drugs. Attached Figure Description

[0019] Figure 1 Triphenyltin complex 1 H NMR spectrum.

[0020] Figure 2 Triphenyltin complex 13 C10 NMR spectrum.

[0021] Figure 3 Triphenyltin complex 119 Sn NMR spectrum.

[0022] Figure 4 This is a confocal fluorescence microscopy image showing the targeted localization of the complex to mitochondria and lysosomes in HepG-2 cells. Specific implementation methods To clearly illustrate how the present invention is implemented, the present invention will be described in detail below through examples.

[0023] Example 1 Preparation and characterization of organotin complexes of 4',4''',4''''-aminotris[3-fluoro-(1,1'-biphenyl)-4-carboxylic acid]

[0024] In a 50 mL round-bottom flask, 0.1210 g (0.2 mmol) of 4',4''',4''''-aminotris[3-fluoro-(1,1'-biphenyl)-4-carboxylic acid], 0.215 g (0.3 mmol) of bis(triphenyltin) oxide, and 20 mL of anhydrous ethanol were added. The reaction was carried out at 70 °C for 12 h. After cooling, the mixture was rotary evaporated, and the solvent was evaporated at room temperature to crystallize, yielding yellow transparent crystals, which were the organotin complex 4',4''',4'''''-aminotris[3-fluoro-(1,1'-biphenyl)-4-carboxylic acid]. Yield: 63%. Melting point: 240-242 °C.

[0025] Elemental analysis: C 93 H 66 F3NO6Sn3: Theoretical value: C 65.45, H 3.90%; Measured value: 65.25, H 3.73%.

[0026] IR (KBr, cm -1 ): 1598(vs), 1519(vs), 1482(vs), 1404(vs), 1324(vs), 1185(vs), 827(s), 784(vs), 729(vs), 696(vs), 526(s), 448(s).

[0027] Figure 1 The triphenyltin complex prepared in this embodiment 1 H NMR spectrum: 1 H NMR (CDCl3, 500MHz, ppm): δ = 8.10 (t, 3H, 3 J H-H = 8.5 Hz, –C 39 H 21 F); 7.84-7.82 (m, 15H, Sn– Ph ),7.52 (d, 6H, 3 J H-H = 8.5 Hz, –C 39 H 21 F); 7.49-7.46 (m, 30H, Sn– Ph ); 7.39-7.37 (m,3H, –C 39 H 21 F); 7.21 (d, 6H, 3 J H-H = 8.5 Hz, –C 39 H 21 F).

[0028] Figure 2 The triphenyltin complex prepared in this embodiment 13 C NMR spectrum: 13 C NMR (CDCl3, 125.7MHz, ppm): δ = 170.0 (– C OO), 163.0 (d, J = 259.4 Hz), 147.6, 146.8 (d, J = 8.5Hz), 138.2 ( 1 J Sn-C = 647.6 Hz, Sn– Ph ), 137.1 ( 3 J Sn-C = 48.4 Hz, Sn– Ph ), 134.0, 133.7, 130.3 ( 4 J Sn-C= 13.2 Hz, Sn– Ph ), 129.1 ( 3 J Sn-C = 63.5 Hz, Sn– Ph ), 128.3,124.7, 121.8 (d, J = 3.0 Hz), 117.3 (d, J = 10.4 Hz), 114.7 (d, J = 23.4 Hz) (– C 39 H 21 F); 19 F NMR (CDCl3, 407.6 MHz, ppm): -108.8.

[0029] Figure 3 The triphenyltin complex prepared in this embodiment 119 Sn NMR spectrum: 119 Sn NMR (CDCl3, 186.5 MHz, ppm): -104.7.

[0030] Crystallographic data: Triclinic system. P -1, a = 12.9229(12) Å, b = 14.2199(13) Å, c =27.022(3) Å, α = 76.774(2) o , β = 82.241(3) o , γ = 73.8650(10), Z = 2, V = 4630.0(7)Å, Dc = 1.224 Mg / m 3 , μ = 0.856 Å, F(000)=1712.

[0031] Example 2 The experimental steps for testing the activity of the organotin complex 4',4''',4''''-aminotris[3-fluoro-(1,1'-biphenyl)-4-carboxylic acid] are as follows: Preparation of drug solutions: Dissolve the test complex in dimethyl sulfoxide (DMSO) to prepare a stock solution of a certain concentration, and then dilute it sequentially with cell culture medium to prepare working solutions with a certain concentration gradient; The in vitro anticancer activity of the target metal complex of the present invention was determined by the MTT assay.

[0032] 1) Human lung cancer cells (A549), human liver cancer cells (HepG2), and human breast cancer cells (MCF) in logarithmic growth phase were collected. 7) Add the human cervical cancer (HeLa) cell suspension to a 96-well plate and incubate at 37°C and 5% CO2 for 24 h to allow the cells to adhere.

[0033] 2) Remove the supernatant, add 100 μL of the above compounds at different concentrations, and incubate for 24 h.

[0034] 3) Add 20 μL of 5 mg / mL MTT solution to each well of the culture plate and continue culturing for 4 h to form purple crystals.

[0035] 4) Wash away the culture medium in the well, add 100 μL of DMSO solution, shake slowly for 10 min to dissolve the dark blue crystals, and measure the absorbance (OD) at 490 nm using an ELISA reader.

[0036] 5) Calculate the cell growth inhibition rate (%) using the formula: [1 - (OD value of the drug-treated group / OD value of the blank group)] × 100%. Each experiment was repeated three times, and the half-maximal inhibitory concentration (IC50) was used. 50 = Average ± SEM.

[0037] 6) The target compound and cisplatin's effects on human lung cancer cells (A549), human liver cancer cells (HepG2), and human breast cancer cells (MCF). 7) The inhibition rates of human cervical cancer (HeLa) cell growth are shown in Table 1.

[0038] Table 1. Growth inhibition rate of the target compound and cisplatin on cancer cells.

[0039] As can be seen from Table 1, under the same conditions, compared with cisplatin, the 4',4''',4''''-aminotris[3-fluoro-(1,1'-biphenyl)-4-carboxylic acid] organotin complex of the present invention showed higher anticancer activity against human liver cancer cells, human lung cancer cells, human breast cancer cells and human cervical cancer cells, and can be used as a candidate compound for anticancer drugs, with potential application value.

[0040] Example 3 Imaging experiments of the target complex targeting mitochondria in HepG-2 cells.

[0041] 1) The complex was applied to HepG-2 cells for 2 hours; 2) Add appropriate volumes of diluted mitochondrial staining solutions Lyso Tracker Red DND-99 (LTRD) and MitoTracker Deep Red (MTDR), and incubate in a cell culture incubator for 30 min.

[0042] 3) Wash the cells three times with serum cell culture medium and observe the intracellular mitochondrial localization under laser confocal microscopy.

[0043] 4) Experimental Results and Discussion: like Figure 4 The results show the localization of the complex in HepG-2 cells as detected by confocal fluorescence microscopy.

[0044] The experimental results above show that the colocalization coefficients of the complex with mitochondria and lysosomes in HepG-2 cells are 0.67 and 0.27, respectively, indicating that it targets mitochondria.

[0045] The complexes described in this invention generally exhibit in vitro anticancer properties and toxicity selectivity, demonstrating good potential pharmaceutical value. They are fluorescently targeted to HepG. 2. Targeted anticancer drugs that induce apoptosis in cell mitochondria and have structures suitable as payloads or targeting ligands for XDC drugs provide an important material basis for the development of antitumor XDC drugs.

[0046] Based on the in vitro activity data of Example 2 (Table 1, IC50) 50 The values ​​are 0.19–0.65 μM) and the mitochondrial targeting imaging results of Example 3 (co-localization of the complex with Mito-Red dye) show that the complex of the present invention can be used as a highly efficient cytotoxic payload to directly kill tumor cells, and can also be used as a mitochondrial targeting ligand to guide the accumulation of XDC drugs in the mitochondria of tumor cells, thereby inducing apoptosis.

[0047] The above description is merely a preferred embodiment of the present invention and does not limit the scope of protection of the present invention. For those skilled in the art, the present invention can have various modifications and variations. Any changes, modifications, substitutions, integrations, and parameter alterations to these embodiments within the spirit and principles of the present invention, achieved through conventional substitutions or by achieving the same function without departing from the principles and spirit of the present invention, fall within the scope of protection of the present invention.

Claims

1. A triphenyltin complex, characterized in that, It is a 4',4''',4''''-aminotris[3-fluoro-(1,1'-biphenyl)-4-carboxylic acid]tin complex, with the structural formula shown in Formula I: Formula I.

2. The triphenyltin complex according to claim 1, characterized in that, Its crystal system is triclinic, space group 1. P -1, a = 12.9229(12) Å, b = 14.2199(13) Å, c = 27.022(3) Å, α = 76.774(2) o , β =82.241(3) o , γ = 73.8650(10), Z = 2, V = 4630.0(7) Å, Dc = 1.224 Mg / m 3 , μ = 0.856Å, F(000)=1712.

3. The triphenyltin complex according to claim 1, characterized in that, It is a yellowish-green transparent crystal with a melting point of 240-242 ℃.

4. The use of the triphenyltin complex according to claim 1 in the preparation of anticancer drugs.

5. The application according to claim 4, characterized in that, The cancer referred to is lung cancer, liver cancer, breast cancer, or cervical cancer.

6. The application according to claim 5, characterized in that, The cancers are derived from human lung cancer cells A549, human liver cancer cells HepG2, human breast cancer cells MCF-7, or human cervical cancer cells HeLa, respectively.

7. The method for preparing the triphenyltin complex according to claim 1, characterized in that, The reaction was carried out using 4',4''',4'''''-aminotris[3-fluoro-(1,1'-biphenyl)-4-carboxylic acid] and bis(triphenyltin) oxide as raw materials.

8. The preparation method according to claim 7, characterized in that, 4',4''',4''''-aminotris[3-fluoro-(1,1'-biphenyl)-4-carboxylic acid] and bis(triphenyltin) oxide were added to anhydrous ethanol and reacted until complete. After cooling, the mixture was rotary evaporated to obtain a pale yellow powder. The pale yellow powder was dissolved in a solvent and volatilized and crystallized to obtain the triphenyltin complex.

9. The preparation method according to claim 7, characterized in that, The molar ratio of 4',4''',4''''-aminotris[3-fluoro-(1,1'-biphenyl)-4-carboxylic acid] to bis(triphenyltin) oxide is 2:(2.9-3.1).

10. The preparation method according to claim 8, characterized in that, The reaction was carried out at 65-70 °C for 12 h, and the crystallization was carried out at room temperature.